Overview of the Agreement Expansion
Knight Therapeutics Inc. (TSX: GUD) is making strides in the specialty pharmaceutical industry by enhancing its partnership with Incyte Biosciences. The recent amendment to their agreement grants Knight the exclusive rights to distribute retifanlimab and axatilimab across Latin America. This strategic move marks an important step for Knight as it works to broaden its impact in the region.
Details of the Expanded Collaboration
Under this revised agreement, Incyte is tasked with developing, manufacturing, and supplying Knight with the sought-after drugs, retifanlimab and axatilimab. Meanwhile, Knight will lead the charge in obtaining regulatory approval and ensuring smooth distribution of these vital medications in various Latin American countries. This collaboration builds on their previous partnership, which included the exclusive distribution of MINVUVI® (tafasitamab) and PEMAZYRE® (pemigatinib) since September 2021.
Introducing Retifanlimab
Retifanlimab is an innovative therapy approved in the United States and Europe specifically to treat adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare yet aggressive skin cancer. With significant data showing an estimated 550 to 1,250 new cases of MCC diagnosed annually in Brazil, Mexico, Colombia, and Argentina, this drug addresses a critical need.
Treatment with Retifanlimab
In addition to its use for MCC, retifanlimab has garnered FDA approval as a first-line therapy in combination with carboplatin and paclitaxel for patients with inoperable metastatic squamous cell carcinoma of the anal canal (SCAC). Data indicate that there are around 2,700 to 4,000 new SCAC diagnoses annually in the same Latin American countries.
Exploring Axatilimab
Axatilimab recently received FDA clearance for managing chronic graft-versus-host disease (cGVHD) following previous systemic therapy failures. This severe complication arises from stem cell transplants, where donor immune cells attack the recipient's body. In Brazil, approximately 1,400 to 1,800 allogeneic transplants are logged yearly, underlining the urgent therapy requirements.
Broadening Applications for Axatilimab
This innovative treatment not only targets cGVHD but is also being researched for potential applications in idiopathic pulmonary fibrosis. Ongoing clinical studies, including frontline combination trials, aim to solidify the role of axatilimab in treating various diseases. Clinical trial initiatives involving this drug are projected to commence soon, indicating a robust future for its clinical usage.
Leadership Perspectives on the Expanded Agreement
Samira Sakhia, Knight Therapeutics’ President and CEO, expressed excitement about extending their collaboration with Incyte, emphasizing the potential impact these therapies could have in Latin America. She noted that adding retifanlimab and axatilimab would complement their existing product line, fortifying their dedication to delivering advanced treatment options in the oncology and hematology domains.
Lee Heeson, Executive Vice President and Head of Incyte International, echoed this sentiment, praising Knight's successful track record and distribution network throughout Latin America. He anticipates this partnership will enhance patient access to innovative therapies.
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. focuses on in-licensing and commercializing essential pharmaceutical products aimed at addressing the diverse healthcare needs of Latin America. Their dedication to delivering essential medications further consolidates their reputation in the region. Knight’s shares are publicly traded on the TSX under the ticker GUD.
Frequently Asked Questions
What recent agreement has Knight Therapeutics entered into?
Knight Therapeutics has amended its agreement with Incyte to include the distribution of retifanlimab and axatilimab in Latin America.
What conditions are treated with retifanlimab?
Retifanlimab is used to treat metastatic or recurrent Merkel cell carcinoma and in combination for squamous cell carcinoma of the anal canal.
How does axatilimab function in treatment?
Axatilimab is designed to manage chronic graft-versus-host disease after prior treatments have failed.
Why is the partnership important for Latin America?
This collaboration enhances access to innovative therapies for patients in Latin America, addressing significant healthcare gaps.
Who leads Knight Therapeutics?
Samira Sakhia serves as the President and CEO, guiding the company's strategic direction in Latin America.
